In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
The evolving vaccine landscape: Insights from the 6th ESCMID Conference on Vaccines
The conference brought together the vaccine community and stakeholders, including industry representatives, clinicians, regulators, policymakers, academics,...